胃窦癌组织中LAG-3 FGL1 MHC-Ⅱ的表达与预后的关系
Relationship of LAG-3,FGL1,and MHC-Ⅱ expression with prognosis in gastric antral cancer
戚颖 1黄子祺 1别鸿宇 1颜次慧 1任秀宝1
作者信息
- 1. 天津医科大学肿瘤医院生物技术研究室,国家恶性肿瘤临床医学研究中心,天津市恶性肿瘤临床医学研究中心,天津市肿瘤免疫与生物治疗重点实验室(天津市 300060)
- 折叠
摘要
目的:探索新型免疫检查点淋巴细胞激活基因3(lymphocyte-activation gene 3,LAG-3)、纤维蛋白原样蛋白1(fibrinogen-like protein 1,FGL1)、主要组织相容性复合体Ⅱ类分子(major histocompatibility complex class Ⅱ,MHC-Ⅱ)在胃窦癌(gastric antral cancer,GAC)中的表达情况与预后的相关性.方法:收集 2012年 1月至 2014年 12月于天津医科大学肿瘤医院诊断为GAC的 67例患者病理标本,分别进行石蜡切片制作,采用免疫组织化学法检测LAG-3、FGL1、MHC-Ⅱ三个指标的表达情况,并用统计学方法分析组间差异.采用Kaplan-Meier法评估LAG-3、FGL1、MHC-Ⅱ的表达水平与GAC患者预后之间的关系并绘制生存曲线.结果:GAC患者中,肿瘤大小<4 cm的患者和无淋巴结转移的患者LAG-3免疫细胞阳性率更高(P<0.05);女性患者MHC-Ⅱ免疫细胞阳性率更高(P<0.05).免疫细胞中LAG-3、MHC-Ⅱ高表达的患者总生存期(overall survival,OS)较好(P<0.05);肿瘤细胞中MHC-Ⅱ高表达的患者OS、无病生存期(disease-free survival,DFS)较差(P<0.05);而FGL1在免疫细胞和肿瘤细胞中的表达与OS、DFS无显著相关性(P>0.05).结论:GAC患者LAG-3、MHC-Ⅱ在不同区域的表达量存在差异,GAC患者LAG-3及其配体在免疫细胞的表达对预后产生积极影响,提示免疫细胞中LAG-3/MHC-Ⅱ可以作为GAC患者预后标志物,为临床个体化免疫治疗提供新的依据.
Abstract
Objective:To investigate the expression of the immune checkpoint lymphocyte-activation gene 3(LAG-3),fibrinogen-like protein 1(FGL1),and major histocompatibility complex class Ⅱ(MHC-Ⅱ)in gastric antral cancer(GAC)and determine their correlation with disease prognosis.Methods:The expression of LAG-3,FGL1,and MHC-Ⅱ was analyzed in 67 patients with GAC admitted to Tianjin Medical Uni-versity Cancer Institute&Hospital from January 2012 to December 2014 using immunohistochemistry.Variations between the groups were analyzed using statistical methods.The Kaplan-Meier method was used to evaluate the relationship between the LAG-3,FGL1,and MHC-Ⅱ expression levels and the prognosis of patients with GAC.Results:LAG-3 expression level in immune cells was higher in patients with GAC presenting with a tumor size of<4 cm and in those without lymph node metastasis(P<0.05).Further,MHC-Ⅱ expression level in immune cells was higher in female than in male patients(P<0.05).Patients with high LAG-3 and MHC-Ⅱ expression levels in immune cells had better overall survival(OS,P<0.05);whereas,patients with high MHC-Ⅱ expression levels in tumor cells had worse OS and disease-free survival(DFS,P<0.05).However,FGL1 expression in immune cells and tumor cells was not significantly correlated with OS and DFS(P>0.05).Conclusions:The LAG-3 and MHC-Ⅱ expression levels in various regions of patients with GAC differ,and the expression of LAG-3 and its lig-ands in the immune cells of patients have a positive impact on prognosis.This suggests that LAG-3 and MHC-Ⅱ in immune cells can be used as prognostic markers of GAC,providing a novel basis for individualized clinical immunotherapy.
关键词
胃窦癌/淋巴细胞激活基因3/纤维蛋白原样蛋白1/主要组织相容性复合体Ⅱ类分子/生存/预后Key words
gastric antral cancer(GAC)/lymphocyte-activation gene 3(LAG-3)/fibrinogen-like protein 1(FGL1)/major histocompatibil-ity complex class Ⅱ(MHC-Ⅱ)/survival/prognosis引用本文复制引用
基金项目
天津市医学重点学科(专科)建设项目(TJYXZDXK-009A)
出版年
2024
NETL
NSTL
万方数据